Synthesis and Cytotoxicity of the Dihydroartemisinin Ester of 1,1′-Ferrocenedicarboxylic Acid

Pharmaceutical Chemistry Journal - The synthesis of the dihydroartemisinin ester of 1,1′-ferrocenedicarboxylic acid (III) is described. Results of in vitro studies of its effect on the...     

Viability of Tumor Cells (K562, Hep-2, HeLa) and Rat Fibroblasts in the Presence of Pterostilbene and Extracts of Licorice Root and Andrographis Paniculata

Pharmaceutical Chemistry Journal - Results from in vitro studies of the effect of pterostilbene, licorice root extract, and Andrographis paniculata extract on the viability of rat fibroblast and...     

Subclass analysis of donor HLA‐specific IgG in antibody‐incompatible renal transplantation reveals a significant association of IgG4 with rejection and graft failure

Donor HLA‐specific antibodies (DSAs) can cause rejection and graft loss after renal transplantation, but their levels measured by the current assays are not fully predictive of outcomes. We investigated whether IgG subclasses of DSA were associated with early rejection and graft failure. DSA levels were determined pretreatment, at the day of peak pan‐IgG level and at 30 days post‐transplantation in eighty HLA antibody‐incompatible kidney transplant recipients using a modified microbead assay. Pretreatment IgG₄ levels were predictive of acute antibody‐mediated rejection (P = 0.003) in the first 30 days post‐transplant. Pre‐treatment presence of IgG₄ DSA (P = 0.008) and day 30 IgG₃ DSA (P = 0.03) was associated with poor graft survival. Multivariate regression analysis showed that in addition to pan‐IgG levels, total IgG₄ levels were an independent risk factor for early rejection when measured pretreatment, and the presence of pretreatment IgG₄ DSA was also an independent risk factor for graft failure. Pretreatment IgG₄ DSA levels correlated independently with higher risk of early rejection episodes and medium‐term death‐censored graft survival. Thus, pretreatment IgG₄ DSA may be used as a biomarker to predict and risk stratify cases with higher levels of pan‐IgG DSA in HLA antibody‐incompatible transplantation. Further investigations are needed to confirm our results.